Related Experiment Video
Updated: Aug 14, 2026
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor
T Wada1, H Yokoyama, K Furuichi
1First Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.
Abstract:
We investigated the pathophysiological role of a potent macrophage (M(phi)) chemotactic cytokine (chemokine), monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1), in an animal model of crescentic glomerulonephritis. Administration of a small dose of nephrotoxic sera induced severe proliferative and necrotizing glomerulonephritis, with crescentic formation in the early phase and glomerulosclerosis in the later phase, in Wistar-Kyoto rats. MCAF/MCP-1 protein was detected immunohistochemically in glomeruli, vascular endothelial cells, and tubular epithelial cells in the early phase of injured kidney tissues but not in normal ones. Anti-MCAF/MCP-1 antibodies decreased the number of M(phi) in glomeruli, and prevented crescentic formation and the fusion of epithelial cell foot process in nephritic rats, thereby decreasing the excreted amounts of protein to normal levels on days 3 and 6. Furthermore, anti-MCAF/MCP-1 antibodies remarkably reduced glomerulosclerosis and improved renal dysfunction as well as proteinuria in the later phase (56 days). These results indicate that MCAF/MCP-1 essentially participates in the impairment of renal functions associated with crescentic glomerulonephritis by recruiting and activating M(phi).
Insights
Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1) drives kidney damage in crescentic glomerulonephritis. Blocking MCAF/MCP-1 reduces inflammation, prevents scarring, and improves kidney function.
Area of Science:
- Nephrology
- Immunology
- Pathophysiology
Background:
- Crescentic glomerulonephritis is a severe kidney disease characterized by inflammation and scarring.
- Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1) is a key chemokine involved in inflammatory responses.
Purpose of the Study:
- To investigate the role of MCAF/MCP-1 in the pathophysiology of crescentic glomerulonephritis.
- To evaluate the therapeutic potential of blocking MCAF/MCP-1 in a rat model of the disease.
Main Methods:
- Induction of crescentic glomerulonephritis in Wistar-Kyoto rats using nephrotoxic sera.
- Immunohistochemical detection of MCAF/MCP-1 in kidney tissues.
- Administration of anti-MCAF/MCP-1 antibodies to assess their effects on disease progression.
Main Results:
- MCAF/MCP-1 protein was significantly elevated in injured kidney tissues during the early phase.
- Anti-MCAF/MCP-1 antibody treatment reduced macrophage infiltration, prevented crescent formation, and preserved podocyte integrity.
- Treatment also attenuated glomerulosclerosis and improved renal function and proteinuria in the later phase.
Conclusions:
- MCAF/MCP-1 plays a critical role in the pathogenesis of crescentic glomerulonephritis by recruiting and activating macrophages.
- Targeting MCAF/MCP-1 offers a promising therapeutic strategy for managing crescentic glomerulonephritis and preventing long-term kidney damage.
